[Featured Stock] Hanmi Pharm Soars on Expectations for COVID-19 Vaccine Contract Manufacturing

[Asia Economy Reporter Ji Yeon-jin] Hanmi Pharm is showing a sharp rise in the KOSPI market on the 22nd.

[Image source=Yonhap News]

As of 2:38 PM on the same day, Hanmi Pharm is trading at 369,000 KRW, up 6.34% from the previous day.

The increase is attributed to the government's announcement of a roadmap starting in August for domestic pharmaceutical companies to produce overseas-approved COVID-19 vaccines, with Hanmi Pharm mentioned as a candidate.

On the 15th, during a background briefing, the government announced that one domestic pharmaceutical company will produce one of the overseas-approved vaccines, naming GC Green Cross and Hanmi Pharm as strong candidates for overseas vaccine contract manufacturing (CMO).